Brazil Eases ANVISA Entry Rule, Adds INPI Patent Check

On July 12, 2026, Brazil introduced a rule change that affects how Herbal Extract shipments enter the market: ANVISA removed the mandatory import pre-registration requirement for exporters already holding Chinese GMP certification, while at the same time linking each declared batch to an INPI patent-status statement. For exporters, importers, procurement teams, compliance staff, and supply-chain operators, the change matters because it reduces one front-end regulatory step but adds a new document-based review point tied to active-ingredient patent status, with a 60-day technical review risk if the statement is missing.

What Portaria No. 112/2026 Changes

According to the information provided, ANVISA issued Portaria No. 112/2026 on July 12, 2026. The measure removes the compulsory import pre-registration requirement for Herbal Extract export companies that have already obtained Chinese GMP certification. At the same time, ANVISA and Brazil's National Institute of Industrial Property, INPI, established a cross-review channel for patents related to active ingredients in plant extracts. Under this arrangement, every declared batch must be submitted together with an INPI patent-status statement. If that statement is not submitted, the batch will enter a 60-day technical review process.

Why the burden shifts rather than disappears

For exporters using Chinese GMP status

From an industry perspective, this group is the most directly affected because the rule explicitly removes a mandatory entry requirement that previously sat before import processing. The practical impact is that market access documentation may become less dependent on pre-registration, but shipment readiness now depends more clearly on whether batch files can include the required INPI patent-status statement. What deserves closer attention is the handoff between regulatory compliance and shipment documentation, because an omitted statement can still delay execution through technical review.

For importers and procurement teams in Brazil

Import-side operators may feel the change in purchasing and delivery planning rather than in product formulation. Analysis shows that a lighter pre-registration burden does not mean lower document risk at the batch level. Importers and buyers will need to verify earlier in the purchasing cycle whether suppliers can provide the INPI-related declaration together with the batch submission package, since missing paperwork could affect arrival timing and inventory scheduling through the 60-day review trigger.

For supply-chain and customs-facing service providers

Logistics coordinators, trade service firms, and teams handling document flow may need to adjust checklists and submission controls. The relevant issue is not only whether a shipment can move, but whether all filing elements are synchronized before declaration. Observably, the new rule places more weight on document completeness and regulatory sequencing at the batch level, which means service providers may need closer coordination with exporters and importers on statement readiness and filing timing.

For compliance and certification-related service functions

Companies involved in compliance review, certification support, and technical file preparation may see the focus shift from pre-registration status to evidence management around GMP qualification and patent-status disclosure. The operational change is that eligibility tied to Chinese GMP certification now appears to open one door, while the INPI declaration becomes a separate control point that can influence release timing. For these functions, the main concern is whether internal review procedures are updated to reflect both conditions together.

Practical points companies should track now

Recheck batch document packages

Analysis shows that the immediate compliance question is not only whether a company benefits from the exemption, but whether each declared batch can be supported by the required INPI patent-status statement. Companies involved in exports, imports, and filing should review whether their standard batch package, shipment checklist, and declaration workflow already contain a place for that statement.

Separate GMP eligibility from patent-related review

What deserves closer attention is that the exemption and the cross-review mechanism are not the same thing. A company may fall within the GMP-related exemption and still face delay if the INPI statement is absent. In practical terms, teams should avoid treating the removal of pre-registration as a complete simplification of entry requirements.

Watch for execution language and filing practice

The input does not provide further implementation detail on format, review practice, or filing interpretation. For that reason, companies should follow subsequent official wording, operational notices, and any changes in submission practice that clarify how the patent-status statement is expected to be prepared, checked, or attached at batch level. At this stage, that remains a monitoring point rather than a confirmed execution outcome.

Adjust lead-time expectations where documentation is incomplete

Observably, the clearest timing signal in the information provided is the 60-day technical review that applies when the INPI patent-status statement is not submitted. Procurement, order management, and delivery planning teams should therefore treat missing documentation as a schedule risk and build that possibility into shipment planning and supplier communication.

How this development is best understood at this stage

Analysis shows that this is not simply a deregulation notice and not simply an intellectual-property alert. It is more appropriate to understand it as a reallocation of control points: one mandatory front-end access requirement is removed for a defined exporter group, while a batch-level patent-status disclosure requirement is inserted into the filing path. From an industry perspective, that makes the development both an implemented rule change and an execution signal, but one whose full operational effect still depends on how consistently the new cross-review mechanism is applied in practice.

A narrower gate in one place, a new checkpoint in another

In summary, the July 12, 2026 development indicates that Brazil is changing how compliance is structured for Herbal Extract imports tied to exporters with Chinese GMP certification. The immediate takeaway is not that compliance has become uniformly lighter, but that the compliance burden has shifted from mandatory pre-registration toward batch-level patent-status documentation. Current industry reading should remain measured: this is best viewed as a rule change that is already defined at the policy level, while its day-to-day impact on clearance timing, procurement execution, and supplier coordination still warrants close observation.

Basis of this article and what still needs verification

This article is based on the user-provided news title, event date, and event summary. For developments of this kind, commonly relevant source types may include official regulatory notices, releases from supervisory authorities, trade or customs-related publications, industry association updates, standard-setting documents, and reporting by established professional media. A specific official source link was not provided in the input, so the underlying text and later implementation details still require continued verification. What remains worth monitoring includes any follow-up rule detail, filing interpretation, certification-related execution language, tender or procurement document changes, market feedback, and how companies implement the new requirement in actual batch declarations.